Facing Lung Cancer Together: A Patient and Care Partner Share Their Journey
“Key Takeaways: Early detection and clinical trials are pivotal in managing small cell lung cancer, as highlighted by Wendy’s experience. A robust support system, including family and healthcare professionals, is crucial in navigating the complexities of cancer diagnosis and treatment.”
Lung Cancer Screening Rates Improved With Targeting Mammography Participants
“Researchers found that 1569 (4.9%) of the 32,165 mammography participants reviewed were confirmed eligible for lung cancer screening (LCS) with chart review; 69% of the 1569 had not previously undergone LCS.”
Emory Healthcare launches new Lung Screening and Nodule Program
“Winship Cancer Institute of Emory University is advancing its commitment to reducing lung cancer deaths across Georgia with the launch of the Emory Healthcare Lung Screening and Nodule Program on Dec. 15, 2025. This new program focuses on early detection and treatment of lung cancer through low-dose lung screening CT and AI-assisted recognition of incidentally found pulmonary nodules.”
Positive lung cancer screens frequently receive suboptimal follow-up
“1. In this retrospective cohort study, most patients with a positive lung cancer screening result received guideline-concordant follow-up, though nearly one-third received less-than-recommended care. 2. Invasive procedures were performed in a small proportion of patients who did not ultimately receive a lung cancer diagnosis.”
Experts hail ‘paradigm shift’ in lung cancer treatment
“A groundbreaking robotic-assisted procedure for lung cancer diagnosis has been trialled in the UK, enabling doctors to make microscopic movements within the lungs. This technology is expected to make lung cancer screening more effective by eliminating the need for months-long repeat scans for small nodules, allowing for quicker and more decisive action.”
NIH-led study reveals role of mobile DNA elements in lung cancer progression
“December 10, 2025 – Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.”
Governor signs law requiring insurers to cover all lung cancer screening services
“New York state recently finalized legislation requiring health insurers to cover all lung cancer screening services with no patient cost-sharing, drawing praise from radiologists. Gov. Kathy Hochul (D) formally signed S2000A/A1195A into law on Dec. 4, with it set to take effect in 2027. The bill requires payers to provide coverage for any follow-up screening or diagnostic services after an abnormal initial low-dose CT scan, while also prohibiting out-of-pocket charges.”
GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA
“GSK plc (LSE/NYSE: GSK) today announced that its B7-H3-targeted antibody-drug conjugate GSK’227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of small-cell lung cancer (SCLC). The ODD was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC (ES-SCLC) who were treated with risvutatug rezetecan in the phase I ARTEMIS-001 clinical trial.”
Secondary cancers outside the chest emerge late for many lung cancer survivors, MSKCC study finds
“Key Takeaways: Lung cancer survivors face increased risk of non-lung secondary cancers, necessitating broader follow-up care beyond the lungs. Study found 23.4% of survivors developed new cancers, with 7.9% experiencing secondary cancers outside the chest.”
Timing of Immune Checkpoint Inhibitor Administration Affects Small Cell Lung Cancer Survival
“HealthDay News — For patients with extensive-stage small cell lung cancer (ES-SCLC), administration of immune checkpoint inhibitor (ICI) therapy earlier in the day is associated with improved survival, according to a study published online December 8 in Cancer.”
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinic ally meaningful improvement in overall survival benefit for Asian patients withEGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
“First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year.”
BioNTech’s CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge
“A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile.”
US approves oral drug for adults with rare type of lung cancer after early clinical trials globally
“The FDA has granted accelerated approval to sevabertinib, an oral drug, for HER2-mutant non-small cell lung cancer (NSCLC) after prior treatment. Phase 1/2 trials showed sevabertinib’s efficacy, particularly in previously untreated patients, with manageable safety, offering a new precision treatment option. Further studies are required to confirm the data for full FDA approval, addressing an unmet need for effective therapies for this aggressive form of lung cancer.”
Video:
ATS Breathe Easy – Delving into the Research on Lung Cancer in People Who Have Not Smoked
“Lung cancer is commonly associated with smoking. However, among people diagnosed with lung cancer, the proportion who have never smoked has been increasing, and there are many reasons why a person who has never smoked may develop this disease. Lori Sakoda, PhD, MPH, ATSF, a research scientist and epidemiologist at Kaiser Permanente Northern California, explains what factors may come into play, what the ongoing research shows, and what knowledge gaps exist on this topic. Patti Tripathi hosts.”
